New: An FDA decision to place 19 peptides on the unsafe list was supported by numerous documented safety concerns, former officials said. Even though demand for peptide therapies has exploded since then, FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn The FDA's Current Position on Peptides Explained Holt Law Gray Market Peptides: So Much Hype, So Little Data